Key result
Direct oral anticoagulants demonstrated varying safety profiles across trials in high-risk atrial fibrillation patients, driven largely by heterogeneous study populations and trial methodologies.
Why the study?
Few data exist regarding the use of NOACs in patients with high risk of stroke, systemic embolism, and bleeding defined by CHADS2 ≥ 3 or HAS-BLED ≥ 3.
Answers are grounded in this paper and cite their sources.
Key Points• Few data exist regarding the use of NOACs in patients with high risk of stroke, systemic embolism and bleeding (CHADS 2 ≥ 3; HAS-BLED ≥ 3).• The indirect comparison meta-analysis between NOACs represents hypothesis generators and they cannot provide definitive answers.• We proposed a critical debate on the data collected from the NOACs in the pivotal trials.
No takes yet. Share an insight, caveat, or question.
Acanfora et al. (2018) conducted a review in Atrial Fibrillation (n=55,522). Direct oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) vs. Warfarin was evaluated on Incidence of major bleeding. Direct oral anticoagulants demonstrated varying safety profiles across trials in high-risk atrial fibrillation patients, driven largely by heterogeneous study populations and trial methodologies.
Synapse has enriched 10 related papers. Consider them for comparative context: